福元医药(601089) - 北京福元医药股份有限公司投资者关系活动记录表

Group 1: Future Plans in Generic Drug Sector - The company will adhere to a "first generic + fast generic" strategy to develop a diverse product line in the generic drug sector [1] - The company has strong R&D capabilities and a rich pipeline, with plans to enhance investment in existing advantageous products and treatment areas [1] Group 2: R&D Investment and Strategy - The company will continue to increase R&D investment, focusing on clinical needs in major diseases and chronic conditions, employing a combination of generic and innovative research strategies [2] - The company is committed to responding actively to national procurement policies, particularly regarding the 10th round of centralized procurement [2] Group 3: Core Advantages - Cost control is ensured through an integrated approach of "raw materials + formulations," maintaining stable supply [2] - The company has a robust R&D strength with a rich pipeline, continuously enhancing investment in existing advantageous products and treatment areas [2] - A comprehensive sales network has been established, with a professional and efficient sales team focused on market penetration and growth [2]